Cargando…

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus

OBJECTIVES: Type I interferons (IFNs) play an important role in the pathophysiology of systemic lupus erythematosus (SLE). While cross-sectional data suggest an association between IFN-induced gene expression and SLE disease activity, interest in this as a biomarker of flare has been tempered by a l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mai, Lloyd, Asaduzzaman, Arundip, Noamani, Babak, Fortin, Paul R., Gladman, Dafna D., Touma, Zahi, Urowitz, Murray B., Wither, Joan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811214/ https://www.ncbi.nlm.nih.gov/pubmed/33451338 http://dx.doi.org/10.1186/s13075-021-02414-0

Ejemplares similares

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis
por: Whittall-Garcia, Laura, et al.
Publicado: (2022)

Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus
por: Medina-Rosas, Jorge, et al.
Publicado: (2015)

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease
por: Al Rayes, Hanan, et al.
Publicado: (2017)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies
por: Tselios, Konstantinos, et al.
Publicado: (2016)

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
por: Tselios, Konstantinos, et al.
Publicado: (2021)

Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50
por: Touma, Z, et al.
Publicado: (2012)

Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms
por: Wither, Joan E., et al.
Publicado: (2018)

Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study
por: Nikpour, Mandana, et al.
Publicado: (2010)

A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis
por: Landolt-Marticorena, Carolina, et al.
Publicado: (2016)

Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study
por: Nikpour, Mandana, et al.
Publicado: (2011)

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments
por: Touma, Zahi, et al.
Publicado: (2017)

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
por: Al Rayes, Hanan, et al.
Publicado: (2014)

T Cell and Dendritic Cell Abnormalities Synergize to Expand Pro-Inflammatory T Cell Subsets Leading to Fatal Autoimmunity in B6.NZBc1 Lupus-Prone Mice
por: Talaei, Nafiseh, et al.
Publicado: (2013)

Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus
por: Yuen, Kimberley, et al.
Publicado: (2021)

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis
por: Wither, Joan, et al.
Publicado: (2017)

Nonlymphoma hematological malignancies in systemic lupus erythematosus
por: Lu, M, et al.
Publicado: (2012)

Lung cancer in systemic lupus erythematosus
por: Kale, M, et al.
Publicado: (2012)

Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis
por: Kim, Sonya T., et al.
Publicado: (2023)

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
por: Touma, Zahi, et al.
Publicado: (2017)

Intraindividual Change in Cognitive Function Among Adults With Systemic Lupus Erythematosus: A Markov Analysis Over 7 Years
por: Perera, Stefan, et al.
Publicado: (2023)

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
por: Strand, Vibeke, et al.
Publicado: (2020)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study
por: Urowitz, Murray B, et al.
Publicado: (2015)

Interferon targeted therapies in systemic lupus erythematosus
por: Misra, Durga Prasanna, et al.
Publicado: (2017)

Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort
por: Fung, William A., et al.
Publicado: (2017)

Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: A systematic review
por: Mendelsohn, Sierra, et al.
Publicado: (2021)

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood
por: Bennett, Lynda, et al.
Publicado: (2003)

Systemic lupus erythematosus and the type I interferon system
por: Rönnblom, Lars, et al.
Publicado: (2003)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
por: Collins, Christopher E., et al.
Publicado: (2020)

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
por: Parker, Ben, et al.
Publicado: (2013)

Apoptotic cell–induced, TLR9-dependent AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans
por: Shinde, Rahul, et al.
Publicado: (2018)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus
por: Harley, Isaac T. W., et al.
Publicado: (2010)

Interferon Regulatory Factor 5 in the Pathogenesis of Systemic Lupus Erythematosus
por: Cham, Candace M., et al.
Publicado: (2012)

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
por: Bruce, Ian N, et al.
Publicado: (2015)

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
por: Werth, Victoria P, et al.
Publicado: (2021)

The dynamic relationship of gut microbiota with sex hormones in systemic lupus erythematosus
por: Katrib, Marcel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_56hcgpbqr1timuhncsmpfoudjo